CatSci, a fast growing and adaptable contract research organisation (CRO), has been shortlisted as a finalist at the annual CPhI Pharma Awards in the prestigious Excellence in Pharma: Contract Services and Outsourcing category.
Founded in 2004, the CPhI Pharma Awards are among the most esteemed recognitions within the pharmaceutical industry, with this year’s edition featuring a record-breaking number of applicants. The nomination reflects CatSci’s wider track record in innovation and excellence within process research and development.
CatSci has been recognised for significantly enhancing the environmental and economical sustainability for the manufacture of the generic API Flurbiprofen. CatSci leveraged its proven combination of commercially-minded and highly-qualified scientific expertise to develop a novel biocatalytic manufacturing process, which addressed route inefficiencies and an upcoming patent expiry date.
The Awards presentation will take place at the Eurostars Madrid Tower Hotel on Tuesday 9th October – the opening day of CPhI Worldwide.
CatSci will be attending both the presentation and CPhI Worldwide in Madrid between 9-11th October. Please get in touch to arrange a meeting to discuss its broad range of process research and development services, which includes route design and assessment, scale-up and non-GMP material supply to support late-stage lead optimisation through to product launch.